Potential Utility of Combination Therapy with Nateglinide and Telmisartan for Metabolic Derangements in Zucker Fatty Rats

Abstract

The metabolic syndrome is strongly associated with insulin resistance and has been recognized as a cluster of risk factors for cardiovascular disease. Insulin resistance and/or impaired early-phase insulin secretion are major determinants of postprandial hyperglycemia. In this study, we investigated the potential utility of combination therapy with telmisartan, an angiotensin II receptor blocker and nateglinide, a rapid-onset/short-duration insulinotropic agent, for the treatment of postprandial hyperglycemia and metabolic derangements in Zucker Fatty (ZF) rats. ZF rats fed twice daily were given vehicle, 50 mg/kg of nateglinide, 5 mg/kg of telmisartan, or both for 6 weeks. Combination therapy with nateglinide and telmisartan for 2 weeks ameliorated postprandial hyperglycemia in ZF rats fed twice daily. Furthermore, 6-week treatment with nateglinide and telmisartan not only decreased fasting plasma insulin, triglycerides, and free fatty acid levels, but also improved the responses of blood glucose to insulin and subsequently reduced the decremental glucose areas under the curve in the ZF rats. Combination therapy also restored the decrease of plasma adiponectin levels in the ZF rats. Monotherapy with nateglinide or telmisartan alone didnot significantly improve these metabolic parameters. These observations demonstrate that combination therapy with nateglinide and telmisartan may improve the metabolic derangements by ameliorating early phase of insulin secretion as well as insulin resistance in ZF rats fed twice daily. Our present findings suggest that the combination therapy with nateglinide and telmisartan could be a promising therapeutic strategy for the treatment of the metabolic syndrome.

insulin resistance - metabolic syndrome - postprandial hyperglycemia - telmisartan

References

• 1 Scheen AJ. Management of the metabolic syndrome.  Minerva Endocrinol. 2004;  29 31-45
• 2 Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance.  Am J Cardiol. 2003;  92 10J-17J
• 3 Heine RJ, Dekker JM. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease.  Diabetologia. 2002;  45 461-475
• 4 Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society.  Diabetes Metab Res Rev. 2001;  17 189-212
• 5 Ceriello A. Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications.  Diabetes Nutr Metab. 1999;  12 42-46
• 6 Ronson RS, Nakamura M, Vinten-Johansen J. The cardiovascular effects and implications of peroxynitrite.  Cardiovasc Res. 1999;  44 47-59
• 7 Kurowska EM. Nitric oxide therapies in vascular diseases.  Curr Pharm Des. 2002;  8 155-166
• 8 Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy.  Curr Pharm Des. 2005;  11 2279-2299
• 9 Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.  Hypertension. 2004;  43 993-1002
• 10 Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.  Circulation. 2004;  109 2054-2057
• 11 Yamagishi S, Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.  Med Hypothese. 2005;  64 476-478
• 12 Takano H, Hasegawa H, Zou Y, Komuro I. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases.  Curr Pharm Des. 2004;  10 2779-2786
• 13 Kitahara Y, Miura K, Takesue K, Mine T, Wada R, Uchida Y, Ito S, Yagihashi S. Decreased blood glucose excursion by nateglinide ameliorated neuropathic changes in Goto-Kakizaki rats, an animal model of non-obese type 2 diabetes.  Metabolism. 2002;  51 1452-1457
• 14 Yamagishi S, Nakamura K, Jinnouchi Y, Takenaka K, Imaizumi T. Molecular mechanisms for vascular injury in the metabolic syndrome.  Drugs Exp Clin Res. 2005;  31 123-129
• 15 Rosen P, Osmers A. Oxidative stress in young Zucker rats with impaired glucose tolerance is diminished by acarbose.  Horm Metab Res. 2006;  38 575-580
• 16 Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.  Hypertension. 2004;  43 993-1002
• 17 Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice.  Hypertension. 2006;  48 51-57
• 18 Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.  Diabetes Care. 2005;  28 757-758

Correspondence